| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 196% | Credit Suisse | $38 → $37 | Maintains | Outperform |
| 05/16/2023 | 204% | Credit Suisse | → $38 | Reiterates | Outperform → Outperform |
| 03/16/2023 | 204% | Credit Suisse | $40 → $38 | Maintains | Outperform |
| 03/07/2023 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 03/07/2023 | 116% | Wells Fargo | → $27 | Initiates Coverage On | → Overweight |
| 03/07/2023 | 220% | Credit Suisse | → $40 | Initiates Coverage On | → Outperform |
| 03/07/2023 | 156% | Guggenheim | → $32 | Initiates Coverage On | → Buy |
| 03/07/2023 | 212% | B of A Securities | → $39 | Initiates Coverage On | → Buy |
| 03/07/2023 | 260% | Stifel | → $45 | Initiates Coverage On | → Buy |
What is the target price for Mineralys Therapeutics (MLYS)?
The latest price target for Mineralys Therapeutics (NASDAQ: MLYS) was reported by Credit Suisse on August 8, 2023. The analyst firm set a price target for $37.00 expecting MLYS to rise to within 12 months (a possible 196.00% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Mineralys Therapeutics (MLYS)?
The latest analyst rating for Mineralys Therapeutics (NASDAQ: MLYS) was provided by Credit Suisse, and Mineralys Therapeutics maintained their outperform rating.
When is the next analyst rating going to be posted or updated for Mineralys Therapeutics (MLYS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Mineralys Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Mineralys Therapeutics was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
Is the Analyst Rating Mineralys Therapeutics (MLYS) correct?
While ratings are subjective and will change, the latest Mineralys Therapeutics (MLYS) rating was a maintained with a price target of $38.00 to $37.00. The current price Mineralys Therapeutics (MLYS) is trading at is $12.50, which is out of the analyst's predicted range.